Lifting the Medical and Economic Burden of AMR in the US

This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.

Addressing a problem of this scale requires a collaborative effort from government officials, public health institutions, industry partners, academics, and healthcare providers. The bipartisan Pasteur Act calls for a new model of antibiotic drug development as well as increased funding to support resource-challenged stewardship programs.

The Pasteur Act would establish a subscription-style model offering an upfront payment to research and develop a pipeline of novel antibiotics. The act also recognizes the need to bolster stewardship efforts to ensure that both existing antibiotics and new drugs will be used appropriately. Collecting and monitoring AMR data from around the country and reporting on antibiotic use using advanced analytics is key to measuring the success of stewardship programs and directing future AMS efforts.